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Introduction	34	 	35	 Biologic	 therapies	are	a	 class	of	protein	drugs	 that	 target	 specific	 chemicals	or	36	 cells	 in	 the	 human	 immune	 system.	 Most	 licensed	 biologic	 agents	 antagonise	37	 cytokines	to	treat	a	range	of	immune-mediated	inflammatory	diseases	(Table	1).	38	 More	 than	 90%	 of	 biologic	 therapies	 used	 for	 inflammatory	 conditions	 target	39	 tumour	 necrosis	 factor-alpha	 (TNF-a)	 (1).	 Like	 other	 biologic	 therapy	 targets,	40	 TNF-a	 has	 protean	 pro-inflammatory	 effects	 in	 vivo,	 such	 as	 inflammatory	 cell	41	 recruitment	and	release	of	additional	cytokines	interleukin-1	(IL-1)	and	IL-6	(2).	42	 Multiple	 therapeutic	 mechanisms	 have	 been	 employed	 to	 down-regulate	 its	43	 effects,	 including	 monoclonal	 antibodies	 that	 target	 TNF-a	 directly	 (e.g.	44	 infliximab),	 and	 neutralising	 soluble	 receptor	 antagonists	 (e.g.	 etanercept).	45	 These	therapies	have	transformed	care	for	HIV-negative	populations	with	severe	46	 inflammatory	conditions.	Approximately	70%	of	anti-TNF-a	agents	used	globally	47	 are	 prescribed	 for	 rheumatoid	 arthritis	 (3).	 In	 the	 UK	 approximately	 6%	 of	48	 patients	with	rheumatoid	arthritis	(RA),	over	12,000	individuals,	receive	biologic	49	 drugs.	 This	 is	 closer	 to	 12%	 in	 The	 Netherlands	 and	 Spain	 where	 clinical	50	 thresholds	for	biologic	therapy	are	lower	(3).	51	 	52	 While	 such	 agents	 dampen	 inflammation,	 they	 may	 also	 impair	 appropriate	53	 immune	 responses	 to	 infection,	 although	 the	 precise	 mechanisms	 are	 poorly	54	 understood	(4,5).	 In	 light	of	this	potential	 increased	infection	risk,	HIV-infected	55	 individuals	 have	 not	 been	 included	 in	 randomised	 controlled	 trials	 of	 biologic	56	 therapies	 alongside	 elderly	 and	 other	 co-morbid	 patients	 that	 are	 thought	 to	57	 constitute	nearly	one	 third	of	 current	 real-life	biologic	 therapy	use	 (6).	Clinical	58	 data	reporting	use	of	biologic	 therapy	for	 inflammatory	disease	 in	HIV-infected	59	 individuals	are	largely	limited	to	case	reports	and	case	series.	Literature	reviews	60	 are	 limited	 to	 single	 specialty	 journals	 and	 do	 not	 cover	 the	 full	 spectrum	 of	61	 inflammatory	 conditions	 that	 affect	 HIV-infected	 individuals.	 There	 is	 a	 more	62	 substantial	 literature	 on	 use	 of	 biologic	 agents	 as	 chemotherapy	 for	63	 haematological	malignancy	in	HIV-infected	individuals	(7).		64	 	65	
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In	this	article	we	review	published	data	on	the	use	of	biologic	therapies	used	to	66	 treat	 inflammatory	 conditions	 in	HIV-infected	 individuals,	 focusing	 on,	 but	 not	67	 limiting	 discussion	 to,	 dermatological,	 gastroenterological	 and	 rheumatological	68	 indications.	The	paper	also	considers	the	clinical	need	for	biologic	therapy	in	the	69	 treatment	 of	 immune-mediated	 pathology	 in	 HIV-infected	 individuals.	 We	70	 address	what	might	be	extrapolated	regarding	efficacy	and	safety	data	from	the	71	 biologic	 therapies	 literature	 of	 HIV-associated	 malignancy	 and	 HIV-uninfected	72	 populations.	73	 	74	
Methods	75	
	76	 The	primary	purpose	of	this	systematic	review	was	to	provide	an	overview	of	all	77	 available	 studies	 of	 biologic	 treatments	 of	 non-malignant	 and	 non-78	 lymphoproliferative	 inflammatory	 conditions	 in	 HIV-positive	 patients.	 The	79	 review	 focuses	 on	 dermatological,	 gastrointestinal,	 and	 rheumatological	80	 indications	for	biologic	therapy.	The	range	of	biologic	treatments	examined	was	81	 limited	to	those	medications	recommended	by	the	National	 Institute	 for	Health	82	 and	 Care	 Excellence	 (NICE)	 up	 to	 1	 July	 2015,	 to	 pragmatically	 capture	 those	83	 therapies	 in	 current	 use.	 Since	 that	 date	 anakinra	 has	 been	 removed	 from	RA	84	 treatment	 guidelines	 however	 the	 agent	was	 included	 in	 our	 literature	 search.	85	 The	study	conduct	was	in	accordance	with	the	PRISMA	statement	for	systematic	86	 reviews.		87	 	88	 Search	strategy:	89	 Studies	 were	 extracted	 from	 search	 of	 online	 databases	 Embase	 and	 Medline	90	 (OvidSP)	up	to	1	July	2015.	The	search	was	restricted	to	adult	articles	from	the	91	 English	 literature	 (Figure	 1;	 Supplementary	Material:	 Additional	 file	 1:	 Search	92	 Strategy).		93	 	94	 Initial	screening	of	the	titles	and	abstracts	excluded	animal	studies,	basic	science	95	 studies,	 duplicate	 publications,	 and	 identified	 studies	 primarily	 on	 biologic	96	 therapy	for	inflammatory	disease	in	HIV-infected	individuals.	The	full	texts	of	the	97	 remaining	52	articles	were	assessed	by	two	authors	for	eligibility.	Thirty-seven	98	
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papers	were	 collected	 for	 final	 review.	 All	 English	 language	 case	 reports,	 case	99	 series	 and	 both	 prospective	 and	 retrospective	 observational	 studies	 were	100	 included.	 References,	 guidelines	 and	 expert	 opinion	 were	 consulted	 for	101	 additional	information.		102	 	103	
Results	104	 	105	 Clinical	 need	 is	 poorly	 defined	 in	 HIV-infected	 individuals.	 Prevalence	 data	 on	106	 inflammatory	 conditions	 in	HIV-infected	populations	 are	 based	 largely	 on	 case	107	 reports,	 case	 series	 and	 single-centre	 studies.	 These	 heterogeneous	 data	 are	108	 further	limited	by	the	variable	application	of	standardised	disease	classifications	109	 (8).	 This	may	 be	 due	 to	 the	 absence	 of	 specific	 diagnostic	 tests	 or	 the	 lack	 of	110	 collaboration	with	specialty	physicians	(9).	The	natural	history	of	inflammatory	111	 diseases	 in	 HIV-infected	 individuals	 is	 also	 complex.	 Onset	 of	 inflammatory	112	 pathology	 may	 be	 HIV-associated	 or	 independent	 of	 HIV	 infection,	 either	113	 preceding	 or	 postdating	 HIV	 acquisition.	 Case	 reports	 describe	 occult	114	 inflammatory	 disease	 unmasked	 both	 by	 HIV-mediated	 immunosuppression	115	 (10)	 and	 paradoxically	 after	 restitution	 of	 the	 immune	 system	 by	 initiation	 of	116	 antiretroviral	 therapy	 (ART)	 (11,12).	 Inflammatory	 manifestations	 associated	117	 with,	or	intrinsic	to,	HIV	infection	are	well	recognised	and	may	mimic	recognised	118	 conditions,	 in	 particular	 rheumatologic	 manifestations	 (13).	 Describing	 the	119	 confounding	 effect	 of	 HIV	 infection	 and	 ART	 on	 any	 of	 these	 processes	 is	120	 complicated	 and	 there	 are	 no	 comprehensive	 long-term	 prospective	 data	 (9).	121	 Despite	 this	 paucity	 of	 information	 inflammatory	 conditions	 are	 considered	122	 common	 in	 HIV-infected	 individuals	 with	 possibly	 different	 disease	 courses	123	 compared	with	HIV-uninfected	populations.			124	 Specific	inflammatory	conditions	in	HIV-infected	individuals	125	 Rheumatologic	 symptoms	 are	 common	 in	 HIV-infected	 individuals.	 In	 a	 large	126	 retrospective	analysis	of	North	American	 inpatients,	 arthritis	or	 arthralgia	was	127	 reported	 in	 5.5%	 of	 HIV-infected	 individuals	 (13).	 High	 positive	 rates	 of	 non-128	 specific	 autoantibodies,	 such	 as	 antinuclear	 antibodies	 (ANA)	 and	 rheumatoid	129	 factor	 (RF),	were	described	 in	HIV-infected	 individuals	 in	 studies	prior	 to	ART	130	
	 5	
(14),	however	seroprevalence	after	initiating	modern	ART	regimens	are	thought	131	 to	 be	 comparable	 to	 rates	 in	 the	 general	 population	 (15).	 Pre-ART	 era	 data	132	 suggested	that	rheumatoid	arthritis	and	HIV-infection	were	mutually	exclusive:	133	 the	decline	in	CD4+	T	cells	mitigating	lymphocyte-mediated	autoimmunity	(16).	134	 This	dogma	may	have	 significantly	prejudiced	 the	nomenclature	of	 subsequent	135	 studies.	 Since	 the	 introduction	 of	 ART	 multiple	 case	 reports	 and	 case	 series	136	 describe	new	presentations	of	symmetrical	polyarthritis	clinically	suggestive	of	137	 Rheumatoid	 Arthritis.	 This	 may	 affect	 between	 0.1%	 and	 5%	 of	 HIV-infected	138	 populations,	 vary	 geographically,	 and	 presentation	 usually	 occurs	 after	 HIV	139	 suppression	 (9).	 Reveille	 et	 al	 have	 proposed	 that	 HIV	 arthritis	 represents	 a	140	 distinct	 self-limiting	 acute	 arthropathy	 affecting	 principally	 large	 joints	 (17).	141	 Ankylosing	 spondylitis,	 psoriatic	 arthritis	 and	 reactive	 arthritis	 occur	 in	 HIV	142	 infected	 populations	 although	 accurate	 prevalence	 and	 natural	 history	 studies	143	 are	not	available,	with	undifferentiated	spondyloarthropathy	commonly	used	as	144	 a	unifying	term	(9).		145	 HIV-associated	 psoriasis	 most	 commonly	 appears	 as	 abrupt	 widespread	 skin	146	 disease	 or	 as	 a	 severe	 exacerbation	 in	 patients	 with	 known	 psoriasis	 (18).	147	 Paradoxically,	for	pathology	caused	by	T	cell	activation,	psoriasis	presentation	is	148	 associated	 with	 increasing	 immunodeficiency	 (18).	 These	 mechanisms	 are	149	 poorly	understood	but	may	 relate	 to	 the	proportional	 increase	 in	CD8+	T	 cells	150	 late	in	HIV	infection	that	are	thought	to	mediate	skin	disease	(19).	In	advanced	151	 HIV	 infection,	 generalised	 skin	 failure	 is	 relatively	 more	 common	 as	 are	 co-152	 existence	 of	 several	 psoriasis	 phenotypes	 (20).	 Unlike	 other	 inflammatory	153	 conditions	in	the	setting	of	HIV	infection,	ART	is	included	in	formal	guidance	for	154	 treatment	of	HIV-associated	psoriasis	(21).		155	 Of	 the	 inflammatory	conditions	considered	 in	 this	 review,	 there	 is	 least	known	156	 about	the	relationship	between	HIV	infection	and	inflammatory	bowel	disease.	A	157	 recent	review	of	the	subject	identified	only	47	eligible	patients	for	study	across	158	 all	 relevant	 literature	 (22).	 A	 small	 retrospective	 case-control	 study	 suggested	159	 that	 HIV	 infection	 predicted	 lower	 relapse	 rates	 of	 all	 causes	 of	 inflammatory	160	 bowel	 disease	 over	 18	 years	 follow	 up	 (23).	 The	 authors	 speculated	 that	161	 impaired	cell-mediated	immunity	may	be	responsible.		162	
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Non-biologic	treatment	of	inflammatory	conditions	in	HIV-infected	individuals	163	 We	 identified	 no	 randomised	 placebo-controlled	 trials	 evaluating	 safety	 and	164	 efficacy	 of	 any	 treatments	 for	 inflammatory	 conditions	 in	 HIV-infected	165	 individuals.	The	small	randomized	controlled	studies	of	disease-modifying	anti-166	 rheumatic	 drug	 use	 in	 HIV-infected	 patients	 were	 conducted	 to	 evaluate	 their	167	 role	 as	HIV	 therapies,	 they	did	not	 include	patients	with	 autoimmune	diseases	168	 and	 the	 study	 durations	 were	 short	 (24–26).	 However,	 in	 patients	 with	 well-169	 controlled	 HIV	 infection	 use	 of	 standard	 immunosuppression,	 including	170	 methotrexate	 for	 treatment	of	 inflammatory	disease,	 is	 supported	with	caution	171	 (9,21,27).	 Corticosteroids	 are	 widely	 used	 in	 HIV-infected	 individuals	 to	 treat	172	 inflammatory	 conditions.	 The	metabolic	 and	 endocrine	 toxicity	 of	 these	 drugs	173	 should	be	monitored	closely	in	all	patients	with	HIV	infection	(28),	in	particular	174	 those	patients	receiving	ritonavir-containing	ART	regimens,	which	may	potently	175	 increase	the	action	and	duration	of	corticosteroids.	Cushing’s	syndrome	has	been	176	 reported	 following	 single	 injections	 of	 triamcinolone	 and	 methylprednisolone	177	 and	these	should	not	be	co-administered	(29).	178	
Systematic	review	of	biologic	therapies	for	inflammatory	conditions	in	HIV-179	
infected	individuals	180	 Overview	181	 	182	 The	 literature	 search	 identified	 two	 case	 series	 and	 15	 case	 reports	 of	 HIV-183	 infected	individuals	receiving	biologic	therapy	for	inflammatory	conditions.	One	184	 further	 case	 report	published	 after	 our	original	 literature	 search	was	 executed	185	 was	also	 included	(30).	This	represents	37	 treatment	episodes	with	6	different	186	 biologic	 agents	 encompassing	 10	 inflammatory	 conditions	 (see	 Table	 2).	 Two	187	 case	 reports	 describe	 the	 same	 individual	 patient	 over	 12	 years	 of	 follow	 up	188	 (31,32).	Five	treatment	episodes	were	 identified	 in	a	report	of	Spanish	biologic	189	 registry	 data	 but	 no	 individual	 clinical	 details	 were	 available	 for	 detailed	190	 outcomes	analysis	 (6).	Only	 for	 individual	patients	with	diagnoses	of	psoriasis,	191	 psoriatic	arthritis	and	rheumatoid	arthritis	were	more	than	two	cases	returned.	192	 Of	37	treatment	episodes	33	(89%)	entailed	use	of	anti-TNF-a	agents.		193	 	194	
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HIV	diagnosis	and	control	195	 	196	 For	 25	 individual	 patients	 with	 adequate	 clinical	 details,	 HIV	 acquisition	197	 preceded	 onset	 of	 inflammatory	 symptoms	 in	 seven,	 post-dated	 inflammatory	198	 symptoms	in	nine	and	in	nine	other	patients	the	relative	timing	is	unknown.	Two	199	 individuals	started	and	failed	biologic	therapy	before	HIV	testing	was	performed	200	 (33,34).	 	 The	 psoriatic	 symptoms	 of	 both	 of	 these	 patients	 responded	201	 dramatically	 to	 ART.	 Besides	 different	 systemic	 diagnoses,	 the	 small	 group	 of	202	 patients	described	 in	 the	 literature	may	also	 represent	disparate	 inflammatory	203	 syndromes:	 individuals	 with	 recognised	 pre-existing	 inflammatory	 disease	204	 (35,36),	 occult	 inflammatory	 conditions	 unmasked	 by	 both	 HIV-mediated	205	 immunosuppression	 (33,37)	 and	 ART	 (31,32,38),	 and	 inflammatory	 symptoms	206	 intrinsically	 related	 to	 HIV	 infection	 (33,34,39).	 It	 is	 unknown	 whether	 these	207	 represent	clinical	entities	that	can	be	directly	compared	in	a	study	of	therapeutic	208	 efficacy.		209	 	210	 Baseline	CD4	 lymphocyte	 count	 and	HIV	viral	 load	values	were	 available	 in	 all	211	 but	 two	patients	 receiving	biologic	 therapy	 for	 inflammatory	conditions	 (Table	212	 2).	The	median	CD4	count	prior	to	initiation	of	biologic	therapy	was	446	cells/μL.	213	 Two	 patients	 developed	 inflammatory	 symptoms	with	 advanced	 HIV	 infection	214	 and	CD4	counts	of	50	cells/μL	or	 less.	Both	received	only	two	doses	of	biologic	215	 therapy	(33,37).	Twenty	patients	(20/25,	80%)	were	established	on	ART	at	the	216	 time	 of	 commencing	 biologic	 therapy	 and	 15	 of	 these	 individuals	 had	 an	217	 undetectable	 HIV	 viral	 load.	 Two	 individuals	 commenced	 ART	 during	 their	218	 treatment	 with	 biologic	 agents.	 Of	 those	 established	 on	 ART	 before	 or	 during	219	 biologic	 therapy,	 the	 precise	 regimen	 was	 only	 described	 in	 13	 individuals	220	 (13/22,	59%).	Two	ART	regimen	changes	were	reported	during	biologic	therapy	221	 however	these	were	not	attributed	to	any	interaction	with	the	biologic	agent.	No	222	 negative	 immunological	 or	 virological	 outcomes	 were	 described	 across	 the	223	 available	 literature.	 However	 CD4	 count	 and	 viral	 load	 monitoring	 was	224	 inconsistent	and	often	infrequent	across	the	literature.	225	 	226	
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In	a	case	control	study	of	HIV-tuberculosis	co-infected	individuals	not	yet	started	227	 on	 ART,	 16	 study	 patients	 received	 8	 doses	 of	 etanercept	 over	 4	 weeks	 in	228	 conjunction	with	routine	quadruple	anti-tuberculosis	therapy	(40).	The	42	CD4	229	 count	matched	control	patients	were	already	receiving	oral	prednisolone	as	part	230	 of	a	separate	trial.	Even	in	the	absence	of	ART	only	a	single	patient	experienced	a	231	 significant	rise	in	their	viral	load,	leading	to	cessation	of	etanercept	at	2	weeks.		232	 	233	 Efficacy	234	 	235	 Treatment	 duration	 ranged	 from	 induction	 therapy	 of	 three	 doses	 to	 years	 of	236	 maintenance	 therapy	with	 a	median	 follow	up	 of	 13	months	 after	 initiation	 of	237	 biologic	therapy.	The	methods	of	reporting	treatment	efficacy	were	variable.	The	238	 largest	case	series	of	eight	patients	was	designed	as	a	“study	of	safety”	and	thus	239	 does	not	include	any	disease	activity	scores	at	baseline	or	after	biologic	therapy	240	 (38).	 In	 the	 remaining	 cases,	 specific	 disease	 activity	 scores	 were	 recorded	 at	241	 baseline	and	at	least	once	after	initiation	of	biologic	therapy	in	only	five	out	of	37	242	 treatment	 episodes	 (13.5%).	 Remission	 was	 achieved	 in	 all	 five	 cases.	 Where	243	 specific	disease	activity	scores	were	unavailable	a	range	of	informal	descriptions	244	 were	 used.	 Table	 3	 summarises	 the	 response	 of	 inflammatory	 conditions	 to	245	 biologic	 therapy:	 ‘unresponsive’	 implies	 failure	 to	 respond	 to	 therapy	 from	246	 induction,	‘partial’	implies	therapy	did	not	reach	unspecified	therapeutic	targets,	247	 ‘transient’	 implies	 therapy	 did	 reach	 therapeutic	 targets	 but	 failed	 to	 sustain	248	 response,	and	 ‘good’	 implies	therapy	reached	and	sustained	therapeutic	targets	249	 which	might	include	remission	(Table	3).	Of	all	treatment	episodes	20/37	(54%)	250	 demonstrated	a	‘good’	primary	response	to	treatment	and	only	4/37	(11%)	were	251	 ‘unresponsive’.	 Biologic	 therapy	 was	 stopped	 or	 switched	 in	 14/37	 (38%)	252	 treatment	episodes.	This	rate	 is	comparable	with	non	HIV-infected	populations	253	 (41).	 In	 these	14	 instances,	 three	were	prompted	by	adverse	events	and	11	by	254	 efficacy.	 Etanercept	 accounted	 for	 50%	 (7/14)	 of	 the	 biologic	 agents	 stopped.	255	 However	Etanercept	was	 also	 the	most	 common	biologic	 agent	 used	 across	 all	256	 conditions	 (43%,	 16/37).	 Dosing	 information	 was	 available	 for	 11	 out	 of	 37	257	 treatment	episodes	(30%)	and	largely	conformed	to	international	guidelines.		258	 	259	
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Concurrent	 with	 biologic	 agents	 18	 patients	 (18/25,	 72%)	 received	 other	260	 synthetic	 disease-modifying	 anti-rheumatic	 drugs	 (DMARDs),	 including	 steroid	261	 therapy	(14	patients)	and	methotrexate	(eight	patients).	Dosing	and	duration	of	262	 these	agents	was	very	poorly	reported.		263	 	264	
	265	
Adverse	events		266	 Analysis	of	adverse	events	described	in	the	literature	search	encompassed	those	267	 42	 treatment	 episodes	 involving	 treatment	 of	 inflammatory	 conditions	268	 (including	five	patients	from	the	Spanish	biologic	registry	data	and	a	total	of	37	269	 treatment	 episodes	 described	 in	 other	 papers)	 and	 33	 treatment	 episodes	270	 involving	 treatment	 of	 HIV-infected	 individuals	 with	 biologic	 agents	 as	 trial	271	 therapy	 for	 HIV	 infection	 or	 tuberculosis.	 For	 those	 individuals	 where	 the	272	 identity	of	 the	biologic	 agent	was	known,	94%	were	anti-TNF-a	 agents	 (66/70	273	 treatment	episodes).		274	 Infectious	complications	275	 We	 identified	 three	 infection	 episodes	 requiring	 hospital	 admission	 that	 were	276	 attributed	 to	 biologic	 therapy:	 facial	 abscess,	 listeriosis,	 and	 “frequent	277	 polymicrobial	infections”	(37,38,42).	This	equates	to	three	infectious	episodes	in	278	 the	cumulative	50	patient-years	of	all	biologic	therapies	reported	in	our	review.	279	 This	 is	 similar	 to	HIV-uninfected	populations	where	relative	risk	of	 infection	 is	280	 reported	for	individual	biologic	agents.	In	the	German	Biologics	Register	RABBIT	281	 (Rheumatoide	 Arthritis:	 Beobachtung	 der	 Biologika-Therapie)	 study	 the	282	 reported	 relative	 risk	 of	 serious	 infection	 is	 2.70	 for	 all	 infliximab	 treatment	283	 (20.59	 episodes	 per	 100	 patient-years)	 (43).	 By	 comparison,	 for	 synthetic	284	 DMARDs	in	HIV-uninfected	patients	registry	data	suggests	that	the	incidence	of	285	 serious	infection	is	5.08	per	100	patient-years	(4).		286	 Given	 the	very	small	 case	numbers,	our	review	cannot	categorically	report	any	287	 clear	association	between	CD4	count	at	time	of	initiation	of	biologic	therapy	and	288	 increased	incidence	of	infectious	complications.	The	patient	with	“polymicrobial	289	 infections”	had	a	baseline	CD4	count	of	50	cells/μL.	No	clinical	detail	is	provided	290	
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on	the	nature	of	these	infections.	However,	the	only	other	patient	with	a	CD4	cell	291	 count	less	than	200	cells/μL	among	patients	treated	for	inflammatory	conditions,	292	 with	29	cells/μL,	did	not	develop	any	infectious	sequelae.		293	 Combined	 corticosteroid	 and	 DMARD	 use	 with	 anti-TNF	 therapy	 is	 associated	294	 with	 increased	 risk	 of	 infectious	 complications	 in	 HIV-uninfected	 cohorts:	 an	295	 odds	 ratio	 (OR)	 of	 14.5	 for	 combined	 therapy	 compared	with	 2.9	 for	 anti-TNF	296	 monotherapy	 in	 HIV	 negative	 patients	 (44).	 All	 four	 patients	 identified	 in	 our	297	 review	with	any	infectious	complications	attributed	to	biologic	therapy	received	298	 concomitant	corticosteroid	therapy.	However	seven	other	patients	in	our	review	299	 who	 also	 received	 concurrent	 corticosteroid	 therapy	 developed	 no	 infectious	300	 complications.	Corticosteroid	dosing	was	not	consistently	reported.		301	 Age	 greater	 than	 50	 years	 is	 associated	 with	 a	 threefold	 increased	 risk	 for	302	 serious	infections	in	patients	receiving	anti-TNF	therapies	(44).	Advancing	age	is	303	 an	 independent	 risk	 factor	 for	 Listeria	monocytogenes	 infection	 in	 any	 setting	304	 (45).	 The	 case	 of	 neuroinvasive	 listeriosis	 occurred	 in	 a	 patient	 aged	 69	 years	305	 (42).		306	 In	 HIV-uninfected	 patients,	 the	 highest	 incidence	 of	 infectious	 complications	307	 occurs	 within	 six	 months	 of	 starting	 biologic	 therapy	 (46).	 	 All	 infectious	308	 complications	 occurred	within	 six	months	 of	 initiating	 biologic	 therapy	 in	 our	309	 review.	There	is	little	discussion	of	antibiotic	prophylaxis	in	the	cases	returned.	310	 However	 one	 individual	 received	 dapsone	 prophylaxis	 following	 pneumocystis	311	 pneumonia,	despite	a	well-preserved	CD4	cell	count	at	 time	of	biologic	therapy	312	 initiation	(38).	In	the	trial	of	etanercept	as	adjuvant	therapy	for	tuberculosis	as	313	 described	 above,	 two	 patients,	 with	 a	 mean	 CD4	 count	 of	 394	 cells/μL,	 were	314	 withdrawn	after	four	doses	of	etanercept	owing	to	increasing	burden	of	acid	fast	315	 bacilli	 in	 sputum	 samples	 (40).	We	did	not	 consider	 this	 evidence	 of	 a	 serious	316	 adverse	event	nor	clearly	attributable	to	the	biologic	therapy.	In	this	study	there	317	 were	no	increased	infectious	complications	in	those	16	HIV-infected	individuals	318	 receiving	etanercept	compared	with	the	42	HIV-infected	control	patients.		319	 Non-infectious	complications	320	
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Allergic	reactions,	all	within	the	first	four	doses	of	therapy,	were	experienced	by	321	 three	 HIV-infected	 individuals	 (35,38,47).	 Anaemia	 and	 acute	 anterior	 uveitis	322	 have	 been	 described	 as	 adverse	 events	 but	 no	 clinical	 detail	 was	 provided	323	 (36,38).	 In	 a	 recent	meta-analysis	 of	 HIV-uninfected	 patients,	 biologic	 therapy	324	 was	 associated	 with	 a	 small	 increased	 risk	 of	 melanoma	 but	 not	 other	325	 malignancy.	 No	 malignant	 complications	 were	 identified	 in	 our	 systematic	326	 review.	Two	HIV-infected	patients	died	during	the	course	of	biologic	therapy	for	327	 non-haematological	 indications.	 Both	 deaths	 occurred	 in	 patients	 receiving	328	 etanercept	 as	 trial	 therapy	 for	 non-inflammatory	 conditions	 (HIV	 and	329	 tuberculosis,	 respectively)	 and	 the	 cause	 of	 death,	 mesenteric	 atherosclerosis	330	 and	pulmonary	embolism,	were	not	deemed	to	be	related	directly	to	anti-TNF-a	331	 therapy	(40,48).		332	
Discussion	333	 Across	all	organ	systems	autoimmune	 inflammatory	pathology	 is	 thought	 to	be	334	 common	in	HIV-infected	 individuals.	However	the	understanding	of	 the	natural	335	 history	of	these	diverse	conditions	in	the	setting	of	HIV	infection,	as	well	as	long-336	 term	 follow-up	of	 their	 clinical	manifestations	 is	 limited.	Even	 for	non-biologic	337	 treatment	of	HIV-infected	patients	living	with	inflammatory	conditions	there	are	338	 only	 limited	 efficacy	 and	 safety	 data.	 Biologic	 therapies	 have	 already	339	 transformed	 the	 lives	 of	 HIV-uninfected	 patients	 with	 severe	 autoimmune	340	 conditions.	 For	 HIV-uninfected	 patients	 these	 agents	 are	 increasingly	 used	 by	341	 clinicians	 and	 may	 in	 the	 future	 be	 “gold	 standard”	 for	 first-line	 therapy,	342	 irrespective	of	disease	severity.	Therefore	both	current	and	future	clinical	parity	343	 for	 HIV-infected	 individuals	 diagnosed	 with	 inflammatory	 diseases	 warrants	344	 closer	and	more	rigorous	consideration	of	biologic	therapy	use.		345	 	346	 Unfortunately,	 the	 available	 literature	 that	 specifically	 addresses	 the	 use	 of	347	 biologic	 agents	 in	 the	 treatment	 of	HIV-infected	 individuals	with	 inflammatory	348	 conditions	is	of	poor	quality.	For	some	specific	inflammatory	diagnoses,	such	as	349	 ulcerative	colitis,	some	available	data	are	 limited	to	single	patient	case	reports.	350	 Psoriasis	 represents	 the	 most	 studied	 condition	 but	 only	 eight	 treatment	351	 episodes	 were	 identified	 in	 the	 literature.	 Although	 detailed	 disease	 scoring	352	
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systems	were	often	absent,	our	review	suggests	that	treatment	responses	were	353	 comparable	 to	 HIV-uninfected	 patients	 receiving	 biologic	 therapy.	 Publication	354	 bias	 towards	positive	outcomes	 is	a	 legitimate	concern	given	 the	small	 sample.	355	 Unsurprisingly	 there	 are	 no	 “control”	 data	 for	 inflammatory	 outcomes	 in	 HIV-356	 infected	 individuals.	 Uncertainty	 also	 remains	 in	 terms	 of	 HIV	 control	 during	357	 biologic	therapy.	A	single	case-control	study	examining	the	use	of	biologic	agents	358	 for	 treatment	 of	 HIV-tuberculosis	 co-infection	 in	 patients	 not	 receiving	 ART	359	 suggested	 that	etanercept	did	not	adversely	affect	HIV	control.	As	 there	are	no	360	 equivalent	 studies	 for	 individuals	 established	 on	 ART,	 suggesting	 biologic	361	 therapies	do	not	adversely	 interact	with	ART	currently	 lacks	an	evidence-base.	362	 However,	no	negative	effects	on	ART	therapy	were	identified	in	our	review.		363	 	364	 The	higher	quality	literature	pertaining	to	the	use	of	biologics	for	haematological	365	 indications	 is	 limited,	 almost	 exclusively	 to	 rituximab,	 whereas	 guidelines	 for	366	 treatment	 of	 severe	 inflammatory	 conditions	 in	 HIV-uninfected	 groups	 is	367	 predicated	 largely	 on	 use	 of	 anti-TNF-a	 agents.	 Patients	 with	 haematological	368	 malignancy	 and	 lymphoproliferative	 disorders	 may	 also	 represent	 a	 relatively	369	 more	 immunocompromised	 cohort	 of	 patients	 and	 who	 receive	 concurrent	370	 chemotherapy,	confounding	direct	comparison	with	patients	receiving	the	same	371	 agents	for	inflammatory	indications.		372	 	373	 In	summary,	our	systematic	review	highlights	a	paucity	of	good	quality	data	on	374	 use	 of	 biologic	 therapies	 to	 treat	 inflammatory	 conditions	 in	 HIV-infected	375	 individuals.	All	evidence	reviewed	that	addressed	this	clinical	area	directly	rated	376	 very	 low	 quality	 according	 to	 the	 GRADE	 system	 (49).	 Due	 to	 this	 major	377	 limitation,	the	review	of	a	cross-section	of	common	inflammatory	conditions	and	378	 agents,	we	cannot	conclude	or	exclude	comparable	efficacy	and	safety	of	biologic	379	 therapies	 between	HIV-infected	 and	 –uninfected	populations.	However	we	 feel	380	 that	 available	 data	 supports	 inclusion	 of	 HIV-infected	 individuals	 with	 well-381	 controlled	HIV	 infection	 in	 future	 studies	 of	 biologic	 therapy.	 There	 remains	 a	382	 broader	 need	 to	 study	 the	 diagnosis,	 natural	 history,	 and	 management	 of	383	 inflammatory	 conditions	 in	 HIV-infected	 populations.	 Rigorous	 and	 formal	384	 prospective	data	collection	of	this	burgeoning	group	of	patients	would	represent	385	
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